CS, K., M, S., M, S., TJ, L., P, F., ES, H., . . . DS, P. (2024). Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious diseases and therapy, 13(10), 2209. https://doi.org/10.1007/s40121-024-01036-8
Chicago Style (17th ed.) CitationCS, Kraft, et al. "Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI." Infectious Diseases and Therapy 13, no. 10 (2024): 2209. https://doi.org/10.1007/s40121-024-01036-8.
MLA (9th ed.) CitationCS, Kraft, et al. "Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI." Infectious Diseases and Therapy, vol. 13, no. 10, 2024, p. 2209, https://doi.org/10.1007/s40121-024-01036-8.